713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

• Ulrich Moebius,
• Radek Špíšek,
• David Béchard,
• Nada Podzimkova,
• Irena Adkins,
• Richard Sachse,
• Joachim Kiemle-Kallee,
• Ekaterina Simonova,
• Lenka Palova Jelinkova,
• Petr Danek,
• Martin Steegmaier

Affiliations

Ulrich Moebius

Aff666 Pieris Pharmaceuticals, Inc Freising Bayern Germany

Radek Špíšek

Sotio Biotech, Prague, Czech Republic

David Béchard

3Cytune Pharma, Nantes, France, France

Nada Podzimkova

1Sotio a.s, Prague, Czech Republic

Irena Adkins

42nd Faculty of Medicine and University Hospital Motol, Prague 5, Czech Republic

Richard Sachse

6SOTIO Biotech AG, Basel, Switzerland, Basel, Switzerland

Joachim Kiemle-Kallee

6SOTIO Biotech AG, Basel, Switzerland, Basel, Switzerland

Ekaterina Simonova

3Sotio Biotech a.s., Prague, Czech Republic

Lenka Palova Jelinkova

3Sotio Biotech a.s., Prague, Czech Republic

Petr Danek

1Sotio Biotech a.s., Prague, Czech Republic

Martin Steegmaier

1Sotio Biotech a.s., Prague, Czech Republic